BOAN BIOTECH: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
BOAN BIOTECH: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
BOAN BIOTECH: INTERIM REPORT 2024
BOAN BIOTECH: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
BOAN BIOTECH: Articles of Association
BOAN BIOTECH: ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024
BOAN BIOTECH: PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
BOAN BIOTECH: NOTICE OF BOARD MEETING
BOAN BIOTECH: Next Day Disclosure Return
BOAN BIOTECH: COMPLETION OF PLACING OFNEW SHARES UNDER GENERAL MANDATE
BOAN BIOTECH: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
BOAN BIOTECH: VOLUNTARY ANNOUNCEMENTAPPROVAL OBTAINED FOR INITIATING CLINICAL TRIALSFOR DULAGLUTIDE INJECTION (BA5101) IN THE U.S.
BOAN BIOTECH: PLACING OF NEW SHARES UNDER GENERAL MANDATE
BOAN BIOTECH: VOLUNTARY ANNOUNCEMENTAPPROVAL OBTAINED FOR INITIATING CLINICAL TRIAL FORTHE NOVEL ADC CANDIDATE BA1302 IN CHINA
BOAN BIOTECH: INSIDE INFORMATION ANNOUNCEMENTPOSITIVE PROFIT ALERT
BOAN BIOTECH: VOLUNTARY ANNOUNCEMENTACCEPTANCE OF BLA IN CHINA FORAFLIBERCEPT INTRAVITREOUS INJECTION (BA9101)
BOAN BIOTECH: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
BOAN BIOTECH: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
BOAN BIOTECH: POLL RESULTS OF THE ANNUAL GENERAL MEETINGHELD ON 31 MAY 2024
BOAN BIOTECH: VOLUNTARY ANNOUNCEMENTACCEPTANCE OF BLA IN CHINA FORDULAGLUTIDE INJECTION (BA5101)
No Data
No Data